![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
The item has been added to your shopping cart.
Home » Agendia Obtains European Rights to Arcturus TUO-gene Profile
Agendia Obtains European Rights to Arcturus TUO-gene Profile
Agendia and Arcturus have signed a license agreement under which Agendia obtained the exclusive European rights to the TUO-gene expression profile (Tumor of Unknown Origin) discovered by Arcturus. Using this profile, Agendia has developed CupPrint, a gene expression-based diagnostic test to be used with patients diagnosed with Cancer Unknown Primary. Financial details of the agreement were not disclosed.
ArriveNet
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct